Journal article icon

Journal article

Effectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent therapy in online and outdoor format in individuals with fibromyalgia: Study protocol of a randomized, controlled trial (On&Out study)

Abstract:
BDNF; Cytokines; FibromyalgiaBDNF; Citocinas; FibromialgiaBDNF; Citocines; FibromiàlgiaIntroduction: The On&Out study is aimed at assessing the effectiveness, cost-utility and physiological underpinnings of the FIBROWALK multicomponent intervention conducted in two different settings: online (FIBRO-On) or outdoors (FIBRO-Out). Both interventions have proved to be efficacious in the short-term but there is no study assessing their comparative effectiveness nor their long-term effects. For the first time, this study will also evaluate the cost-utility (6-month time-horizon) and the effects on immune-inflammatory biomarkers and Brain-Derived Neurotrophic Factor (BDNF) levels of both interventions. The objectives of this 6-month, randomized, controlled trial (RCT) are 1) to examine the effectiveness and cost-utility of adding FIBRO-On or FIBRO-Out to Treatment-As-Usual (TAU) for individuals with fibromyalgia (FM); 2) to identify pre-post differences in blood biomarker levels in the three study arms and 3) to analyze the role of process variables as mediators of 6-month follow-up clinical outcomes. Methods and analysis: Participants will be 225 individuals with FM recruited at Vall d'Hebron University Hospital (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs. TAU + FIBRO-On vs. TAU + FIBRO-Out. A comprehensive assessment to collect functional impairment, pain, fatigue, depressive and anxiety symptoms, perceived stress, central sensitization, physical function, sleep quality, perceived cognitive dysfunction, kinesiophobia, pain catastrophizing, psychological inflexibility in pain and pain knowledge will be conducted pre-intervention, at 6 weeks, post-intervention (12 weeks), and at 6-month follow-up. Changes in immune-inflammatory biomarkers [i.e., IL-6, CXCL8, IL-17A, IL-4, IL-10, and high-sensitivity C-reactive protein (hs-CRP)] and Brain-Derived Neurotrophic Factor will be evaluated in 40 participants in each treatment arm (total n = 120) at pre- and post-treatment. Quality of life and direct and indirect costs will be evaluated at baseline and at 6-month follow-up. Linear mixed-effects regression models using restricted maximum likelihood, mediational models and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Authors

More by this author
Role:
Author
ORCID:
0000-0002-5591-9407
More by this author
Role:
Author
ORCID:
0000-0001-5305-8386
More by this author
Role:
Author
ORCID:
0009-0004-1660-8106
More by this author
Role:
Author
ORCID:
0000-0002-4874-8013


More from this funder
Funder identifier:
10.13039/501100004837
Grant:
PID 2020-117667RA-I00


Publisher:
Frontiers Media
Journal:
Frontiers in Physiology More from this journal
Volume:
13
Pages:
1046613-1046613
Article number:
1046613
Publication date:
2022-11-10
DOI:
EISSN:
1664-042X
ISSN:
1664-042X


Language:
English
Keywords:
Pubs id:
1489681
Local pid:
pubs:1489681
Source identifiers:
W4308868367
Deposit date:
2026-05-11
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP